Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

innovaTIL-04, Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03108495
Recruitment Status : Recruiting
First Posted : April 11, 2017
Last Update Posted : April 18, 2019
Sponsor:
Information provided by (Responsible Party):
Iovance Biotherapeutics, Inc.

Brief Summary:
Prospective, multicenter, single-arm, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma

Condition or disease Intervention/treatment Phase
Cervical Carcinoma Biological: LN-145 Phase 2

Detailed Description:
LN-145 is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI, for the treatment of patients with recurrent, metastatic, or persistent cervical carcinoma. The cell transfer therapy used in this study involves patients receiving a NMA lymphocyte depleting preparative regimen, followed by infusion of autologous TIL followed by the administration of a regimen of IL-2.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 59 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Actual Study Start Date : June 22, 2017
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : September 2024

Arm Intervention/treatment
Experimental: Single Arm
After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration
Biological: LN-145
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
Other Name: TIL, autologous tumor infiltrating lymphocytes




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 6 months ]
    To evaluate the efficacy of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma based on the objective response rate (ORR) as assessed by the Blinded Independent Review Committee (BIRC) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1


Secondary Outcome Measures :
  1. Duration of Response [ Time Frame: Up to 24 months ]
    To evaluate the efficacy parameters of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma by assessing duration of response (DOR) as assessed by the BIRC per RECIST v1.1

  2. Disease Control Rate [ Time Frame: Up to 24 months ]
    To evaluate the efficacy parameters of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma by assessing disease control rate (DCR) as assessed by the BIRC per RECIST v1.1

  3. Progression-Free Survival [ Time Frame: Up to 24 months ]
    To evaluate the efficacy parameters of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma by assessing progression-free survival (PFS) as assessed by the BIRC per RECIST v1.1

  4. Objective Response Rate [ Time Frame: Up to 24 months ]
    To evaluate ORR as assessed by the Investigator per RECIST v1.1 in patients with recurrent, metastatic, or persistent cervical carcinoma

  5. Duration of Response [ Time Frame: Up to 24 months ]
    To evaluate DOR as assessed by the Investigator per RECIST v1.1 in patients with recurrent, metastatic, or persistent cervical carcinoma

  6. Disease Control Rate [ Time Frame: Up to 24 months ]
    To evaluate DCR as assessed by the Investigator per RECIST v1.1 in patients with recurrent, metastatic, or persistent cervical carcinoma

  7. Progression-Free Survival [ Time Frame: Up to 24 months ]
    To evaluate PFS as assessed by the Investigator per RECIST v1.1 in patients with recurrent, metastatic, or persistent cervical carcinoma

  8. Overall Survival [ Time Frame: Up to 60 months ]
    To evaluate overall survival (OS) in patients with recurrent, metastatic, or persistent cervical carcinoma

  9. Adverse Events [ Time Frame: 24 months from infusion LN-145 ]
    Safety profile of LN-145 in patients with recurrent, metastatic, or persistent cervical carcinoma as assessed by incidence of adverse events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible for the study, patients must meet ALL of the following criteria prior to participation:

  1. Must be ≥ 18 years of age at the time of consent
  2. Must have recurrent, metastatic, or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy
  3. At least one resectable lesion (or aggregate of lesions resected) of a minimum 1.5 cm in diameter post resection to generate TIL; surgical removal with minimal morbidity (defined as any procedure for which expected hospitalization is ≤ 3 days)
  4. At least one measurable target lesion, as defined by RECIST v1.1
  5. Must have had at least one and no more than three prior systemic chemotherapeutic treatments (such as carboplatin/cisplatin, paclitaxel, and bevacizumab except where there are contraindications) for cervical carcinoma
  6. Any prior therapy directed at the malignant tumor must be discontinued at least 28 days prior to tumor resection. Radiation therapy may have been received up to 28 days prior to tumor resection for lesions not expected to be used for TIL generation or target lesions
  7. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  8. Patients must be seronegative for the human immunodeficiency virus (HIV). Patients with positive serology for hepatitis B virus surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), or hepatitis C virus antibody (HCV Ab) indicating acute or chronic infection may be enrolled if the viral load by polymerase chain reaction (PCR) is undetectable with/without active treatment.
  9. Patients of childbearing potential must be willing to take the appropriate precaution to avoid pregnancy for the duration of the study and practice an approved, highly effective method of birth control during treatment and for 12 months after receiving the last protocol-related therapy.
  10. Prior to study Enrollment (tumor resection), patient must have documentation of radiological disease progression after the most recent therapy.

Exclusion Criteria:

  1. Patients who have received an organ allograft or prior cell transfer therapy except for prior LN-145 therapy.
  2. Patients who are on chronic systemic steroid therapy
  3. Patients who currently have prior therapy-related toxicities > Grade 1 according to National Cancer Institute (NCI-) Common Terminology Criteria for Adverse Events (CTCAE) v4.03; except for peripheral neuropathy, alopecia, or vitiligo prior to Enrollment (tumor resection)
  4. Patients who have a history of hypersensitivity to any component or excipient of LN-145 or other study drugs:

    • NMA-LD preconditioning regimen (cyclophosphamide, mesna, and fludarabine)

  5. Patients who have active systemic infections, coagulation disorders or other active major medical illnesse(es) of the cardiovascular, respiratory, or immune system, including evidence in the medical history of urinary tract obstruction, a positive cardiac stress test, myocardial infarction, cardiac arrhythmia, obstructive or restrictive pulmonary disease, or other conditions that in the opinion of the Investigator would increase the risk of participation
  6. Patients with symptomatic and/or untreated brain metastases (of any size and any number)

    • Patients with definitively treated brain metastases may be considered for Enrollment, and must be stable for ≥ 14 days prior to beginning the NMA-LD preconditioning regimen

  7. Patients who have any form of primary immunodeficiency (such as severe combined immunodeficiency [SCID] or acquired immunodeficiency syndrome [AIDS])
  8. Patients who have a diagnosis of end-stage renal disorder requiring hemodialysis.
  9. Patients who have a left ventricular ejection fraction (LVEF) < 45% or who are New York Heart Association (NYHA) Class 2 or higher.
  10. Patients who have a documented forced expiratory volume in 1 second (FEV1) of ≤ 60%
  11. Patients who have received a live or attenuated vaccine within 28 days prior to beginning NMA-LD preconditioning regimen.
  12. Patients whose cancer requires immediate attention or who would otherwise suffer a disadvantage by participating in this study
  13. Patients who have received prior treatment with immunotherapy (eg, anti-programmed cell death protein-1 [PD-1], anti-programmed death ligand 1 [PD-L1], or anti-cytotoxic T lymphocyte-associated antigen-4 [CTLA-4] antibodies)
  14. Patients who have had another primary malignancy within the previous 3 years (except for curatively treated localized malignancy that has not required treatment for > 1 year, and in the judgement of the Investigator, does not pose a significant risk of recurrence including, but not limited to, non-melanoma skin cancer or bladder cancer)
  15. Patients who have ≥ Grade 2 hemorrhage within 14 days prior to Enrollment (tumor resection)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03108495


Contacts
Layout table for location contacts
Contact: Iovance Biotherapeutics Clinical Inquiries 650-260-7120 Clinical.Inquiries@iovance.com
Contact: Iovance Biotherapeutics Clinical Inquiries 866-565-4410 Clinical.Inquiries@iovance.com

  Show 35 Study Locations
Sponsors and Collaborators
Iovance Biotherapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Iovance Medical Monitor Iovance Biotherapeutics, Inc.

Layout table for additonal information
Responsible Party: Iovance Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03108495     History of Changes
Other Study ID Numbers: C-145-04
2016-003447-11 ( EudraCT Number )
First Posted: April 11, 2017    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Iovance Biotherapeutics, Inc.:
LN-145
Cell Therapy
Autologous Adoptive Cell Transfer
Autologous Adoptive Cell Therapy
Cellular Immuno-therapy
Tumor Infiltrating Lymphocytes
TIL
IL-2
innovaTIL-04

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms